负载mRNA的脂质纳米颗粒实现人源化CD19 CAR-T细胞工程以清除白血病细胞
研究开发基于脂质纳米颗粒(LNP)递送mRNA编码全人源CAR构建体的非病毒CAR-T工程方法,在体外实现高CAR表达和对白血病细胞的显著细胞毒性,在Raji细胞共培养中显示细胞因子分泌增加和肿瘤细胞杀伤,在NSG小鼠Raji移植模型中治疗组显示明显肿瘤消退和生存期延长。
要点
- LNP递送mRNA编码全人源CAR可实现高CAR表达和体外抗白血病细胞毒性。
- mRNA-LNP CAR-T与Raji细胞共培养显示细胞因子分泌增加和肿瘤细胞杀伤。
- NSG小鼠Raji模型中治疗组显示明显肿瘤消退和生存期延长。
核心结论
- mRNA-LNP可作为非病毒、有效的CAR-T工程平台,为传统方法提供有前景的替代方案,可能改善CAR-T安全性、疗效和可及性。
研究设计与样本
- 研究开发基于LNP的转染方案,递送mRNA编码全人源CAR构建体,进行体外细胞毒性和Raji细胞共培养实验,并在NOD-scid-IL2Rγnull(NSG)小鼠Raji移植模型中评估疗效。
主要发现
- 体外实现高CAR表达和对白血病细胞的显著细胞毒性。
- 与Raji细胞共培养显示mRNA-LNP CAR-T细胞细胞因子分泌增加和肿瘤细胞杀伤。
- NSG小鼠Raji移植模型中,治疗组小鼠显示明显肿瘤消退和生存期延长。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor T-cell (CAR-T) therapy has shown transformative potential in treating malignant tumours, with increasing global approval of CAR-T products. However, high-production costs and risks associated with viral vector-based CAR-T cells-such as insertional mutagenesis and secondary tumour formation-remain challenges. Our study introduces an innovative CAR-T engineering approach using mRNA delivered via lipid nanoparticles (LNPs), aiming to reduce costs and enhance safety while maintaining strong anti-tumour efficacy. We developed an LNP-based transfection protocol for efficient delivery of mRNA encoding full-human CAR constructs, achieving high CAR expression and significant cytotoxicity against leukaemic cells in vitro. Co-culture with Raji cells showed increased cytokine secretion and tumour cell killing by mRNA-LNP CAR-T cells. Therapeutic efficacy was further demonstrated in an NOD-scid-IL2Rγnull (NSG) mouse model with Raji engraftment, where treated mice exhibited marked tumour regression and extended survival. These findings underscore the potential of mRNA-LNPs as a non-viral, effective CAR-T engineering platform, offering a promising alternative to traditional methods that could improve CAR-T safety, efficacy and accessibility in clinical cancer immunotherapy.
引用
- Chen Z, Ren A, Li Y, et al. mRNA-laden lipid nanoparticle-enabled humanized CD19 CAR-T-cell engineering for the eradication of leukaemic cells. Br J Haematol. 2025. PMID: 39761676. doi:10.1111/bjh.19988
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。